ABSTRACT
Objective: To evaluate whether COVID19 vaccination during pregnancy confers immunological response to SARS-CoV-2 Delta variant. Study Design: Prospective cohort study of pregnant patients who had received any available COVID19 vaccine. Maternal and umbilical cord serum was collected at delivery. SARS-CoV-2 neutralization was measured with spike-pseudotyped viruses in HEK-293T-ACE2 cells as a function of reduction in Luc reporter activity using an env-deficient lentiviral system to produce viral particles pseudotyped with the B1.617.2 (Delta variant) spike. Neutralization titers represented the serum dilution at which relative luminescence units (RLU) were reduced by either 50%(ID50) or 80%(ID80) compared with virus control wells. RLU threshold for detection was 20. Result(s): Maternal and neonatal umbilical cord samples were collected from 20 individuals who received COVID19 vaccination during pregnancy. Most (n=16, 80%) received Pfizer, 2 Moderna, 2 Johnson&Johnson. One individual (5%) was vaccinated in first trimester, 11(55%) in second trimester, and 8(40%) in third trimester). Most individuals had detectable levels of neutralizing antibodies to SARS-CoV-2 Delta variant in maternal (n=15, 75%) and neonatal (n=17, 85%) serum. (Figure) No significant difference between maternal and neonatal serum titers. Conclusion(s): COVID19 vaccination during pregnancy yields an immunologic response in maternal serum that results in circulating neutralizing antibodies against SARS-CoV-2 Delta variant in maternal and neonatal serum at delivery. Disclosure: No [Formula presented] Copyright © 2022
ABSTRACT
Background: Coronavirus disease 2019 (COVID-19) has posed a serious threat to human health and there is an urgent need for drug development. In this study, we explored the potential mechanisms underlying the efficacy of polydatin against COVID-19. Methods: A combined approach of network pharmacology, molecular docking, and experimental verification were employed in this study. Potential targets of polydatin for treating COVID-19 were obtained from multiple drug and disease databases. Protein–protein interaction and enrichment analyses were performed to predict the potential mechanism of action of polydatin against COVID-19. The binding potential of polydatin and key targets was evaluated through molecular docking. Furthermore, experimental methods including flow cytometry and luciferase assay were used to validate the results of computational analyses. Results: The main diseases identified as polydatin targets included metabolic diseases, lung diseases, inflammation, infectious diseases, and tumors. Polydatin may be used to treat COVID-19 through interventions that alter the immune and inflammatory responses, including IL-17 signaling pathway, T-cell activation, cytokines and inflammatory response, lipopolysaccharide-mediated signaling pathway, as well as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) innate immunity evasion and cell-specific immune response. Polydatin can potentially bind to the target proteins related to COVID-19, such as SARS-CoV-2 Mpro, RdRp, and human angiotensin-converting enzyme 2 (ACE2), while directly exerting its regulatory or therapeutic functions. The experimental results showed that polydatin decreased the infectivity of the SARS-CoV-2 spike pseudovirus in HEK293T-ACE2 cells. Accordingly, polydatin may retard the entry of SARS-CoV-2 into cells by competitively binding to human ACE2. Conclusion: The potential targets and signaling pathways of polydatin against COVID-19 were preliminarily identified. The findings may benefit the development and application of polydatin as a treatment for COVID-19.